Lisata Therapeutics (LSTA) 10-Q 7 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information Document	9 Months Ended
	Sep. 30, 2013	Nov. 06, 2013
Document Information [Line Items]	'	'
Entity Registrant Name	'NeoStem, Inc.	'
Entity Central Index Key	'0000320017	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Amendment Flag	'false	'
Entity Common Stock, Shares Outstanding	'	27,141,894

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current Assets	'	'
Cash and cash equivalents	$16,946,200	$13,737,452
Accounts receivable, net of allowance for doubtful accounts of $393,524 and $626,054 at September 30, 2013 and December 31, 2012, respectively	1,394,498	1,053,604
Inventory	529,366	1,113,025
Prepaids and other current assets	1,466,677	803,135
Total current assets	20,336,741	16,707,216
Property, plant and equipment, net	11,331,485	11,153,143
Goodwill	11,117,770	11,117,770
Intangible assets, net	14,026,919	14,480,827
Other assets	973,294	947,307
Assets, Total	57,786,209	54,406,263
Current Liabilities	'	'
Accounts payable	3,091,287	2,555,240
Accrued liabilities	2,231,848	2,284,813
Notes payable	402,813	202,558
Mortgages payable	3,288,181	3,438,475
Unearned revenues	1,021,942	1,468,341
Total current liabilities	10,036,071	9,949,427
Long-term Liabilities	'	'
Deferred income taxes	4,091,447	3,599,122
Notes payable	348,299	171,528
Derivative liabilities	114,108	101,156
Acquisition-related contingent consideration	7,550,000	7,550,000
Other long-term liabilities	511,889	214,871
Total long-term liabilities	12,615,743	11,636,677
Commitments and Contingencies	'	'
Stockholders' Equity	'	'
Preferred stock, authorized, 20,000,000 shares; Series B convertible redeemable preferred stock liquidation value, 1/100 share of common stock, $.01 par value; 825,000 shares designated; issued and outstanding, 10,000 shares at September 30, 2013 and December 31, 2012	100	100
Common stock, $.001 par value, authorized 500,000,000 shares; issued and outstanding, 21,193,870 and 16,375,365 shares, at September 30, 2013 and December 31, 2012, respectively	21,194	16,375
Additional paid-in capital	260,212,091	231,218,615
Treasury stock, at cost	-694,767	-665,600
Accumulated deficit	-223,839,053	-197,392,361
Total NeoStem, Inc. stockholders' equity	35,699,565	33,177,129
Noncontrolling interests	-565,170	-356,970
Total equity	35,134,395	32,820,159
Liabilities and Equity, Total	$57,786,209	$54,406,263

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Preferred Stock, Shares Outstanding	10,000	10,000
Common Stock, Par Value	$0.00	$0.00
Accounts receivable trade, net of allowance for doubtful accounts	$393,524	$626,054
Preferred Stock, authorized	20,000,000	20,000,000
Common stock, outstanding	21,193,870	16,375,365
Common Stock, authorized	500,000,000	500,000,000
Common Stock, Shares, Issued	21,193,870	16,375,365
Preferred stock, shares designated	825,000	825,000
Preferred stock, issued	10,000	10,000
Preferred stock, Series B convertible redeemable preferred stock liquidation value, share of common stock	1	1
Preferred stock, par value	$0.01	$0.01

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Revenues	$3,706,918	$4,433,961	$10,590,237	$11,578,783
Cost of revenues	2,975,935	3,747,490	9,603,048	9,439,185
Gross profit	730,983	686,471	987,189	2,139,598
Research and development	4,486,389	2,828,210	11,619,843	7,490,002
Selling, general, and administrative	5,557,425	5,947,264	15,681,731	17,092,493
Operating expenses	10,043,814	8,775,474	27,301,574	24,582,495
Operating loss	-9,312,831	-8,089,003	-26,314,385	-22,442,897
Other income (expense):	'	'	'	'
Other income (expense), net	179,605	-74,881	248,161	36,924
Interest expense	-98,618	-384,168	-208,023	-1,359,187
Nonoperating Income (Expense), Total	80,987	-459,049	40,138	-1,322,263
Loss from continuing operations before provision for income taxes and noncontrolling interests	-9,231,844	-8,548,052	-26,274,247	-23,765,160
Provision for income taxes	44,757	0	492,325	0
Net loss from continuing operations	-9,276,601	-8,548,052	-26,766,572	-23,765,160
Income (loss) from discontinued operations - net	0	152,095	0	-27,260,584
Net loss	-9,276,601	-8,395,957	-26,766,572	-51,025,744
Less - loss from continuing operations attributable to noncontrolling interests	-205,844	-59,572	-319,880	-248,294
Less - loss from continuing operations attributable to noncontrolling interests	0	74,524	0	-12,513,069
Net loss attributable to NeoStem, Inc.	-9,070,757	-8,410,909	-26,446,692	-38,264,381
Warrant Inducements	0	-1,012,819	0	-1,012,819
Preferred dividends	0	-67,197	0	-263,432
Net Income (Loss) Available to Common Stockholders, Basic	-9,070,757	-9,490,925	-26,446,692	-39,540,632
Amounts Attributable to NeoStem, Inc. common stockholders:	'	'	'	'
Loss from continuing operations	-9,070,757	-8,488,480	-26,446,692	-23,516,866
Loss from discontinued operations - net of taxes	0	77,571	0	-14,747,515
Payment for warrant inducement	0	-1,012,819	0	-1,012,819
Preferred dividends	0	-67,197	0	-263,432
Net Income (Loss) Available to Common Stockholders, Basic	($9,070,757)	($9,490,925)	($26,446,692)	($39,540,632)
Continuing operations	($0.45)	($0.57)	($1.43)	($1.79)
Discontinued operations	$0	$0.01	$0	($1.12)
NeoStem, Inc. common stockholders	($0.45)	($0.64)	($1.43)	($3.01)
Weighted average common shares outstanding	20,203,934	14,819,708	18,482,413	13,153,306

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Net loss	($9,276,601)	($8,395,957)	($26,766,572)	($51,025,744)
Other comprehensive income (loss):	'	'	'	'
other comprehensive income, foreign currency translation elimination on sale of segment	0	0	0	-169,993
Foreign currency translation	0	-50,128	0	317,294
Total other comprehensive (loss) income	0	-50,128	0	147,301
Comprehensive loss	-9,276,601	-8,446,085	-26,766,572	-50,878,443
Comprehensive loss attributable to noncontrolling interests	-205,844	-9,611	-319,880	-12,610,486
Comprehensive net loss attributable to NeoStem, Inc. common stockholders	($9,070,757)	($8,436,474)	($26,446,692)	($38,267,957)

Consolidated_Statements_of_Equ

Consolidated Statements of Equity (USD $)	Total	Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Treasury Stock [Member]	Total NeoStem, Inc. Shareholders' Equity [Member]	Noncontrolling Interest [Member]
Beginning Balance at Dec. 31, 2011	$80,132,518	$100	$10,933	$200,957,035	$4,152,343	($143,094,854)	$0	$62,025,557	$18,106,961
Beginning Balance (shares) at Dec. 31, 2011	'	10,000	10,932,959	'	'	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'	'	'	'
Net loss	-51,025,744	'	'	'	'	-38,264,381	'	-38,264,381	-12,761,363
Foreign currency translation	147,301	'	'	'	-3,576	'	'	-3,576	150,877
Share-based compensation (in shares)	'	'	263,403	'	'	'	'	'	'
Share-based compensation	5,471,166	'	263	5,470,903	'	'	'	5,471,166	'
Net proceeds from issuance of common stock (in shares)	'	'	2,876,561	'	'	'	'	'	'
Net proceeds from issuance of common stock	12,160,227	'	2,878	12,157,349	'	'	'	12,160,227	'
Proceeds from Stock Options Exercised	0	'	'	'	'	'	'	'	'
Proceeds from warrant exercise (in shares)	'	'	1,016,052	'	'	'	'	'	'
Proceeds from exercise of warrants	5,925,931	'	1,016	5,924,915	'	'	'	5,925,931	'
Warrant Inducements (in shares)	'	'	145,895	'	'	'	'	'	'
Warrant Inducements	-1,012,819	'	146	-43,862	'	'	'	-43,716	'
Adjustments to Additional Paid in Capital, Warrant Issued	-43,716	'	'	'	'	'	'	'	'
Repayment of Series E Preferred Principal and Dividends (in shares)	'	'	279,238	'	'	'	'	'	'
Repayment of Series E Preferred Principal and Dividends	938,785	'	279	1,201,938	'	-263,432	'	938,785	'
Ending Balance at Sep. 30, 2012	53,706,468	100	15,515	225,668,278	4,148,767	-181,622,667	0	48,209,993	5,496,475
Ending Balance (shares) at Sep. 30, 2012	'	10,000	15,514,108	'	'	'	'	'	'
Beginning Balance at Dec. 31, 2012	32,820,159	100	16,375	231,218,615	0	-197,392,361	-665,600	33,177,129	-356,970
Beginning Balance (shares) at Dec. 31, 2012	'	10,000	16,375,365	'	'	'	'	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'	'	'	'
Net loss	-26,766,572	'	'	'	'	-26,446,692	'	-26,446,692	-319,880
Share-based compensation (in shares)	'	'	451,666	'	'	'	'	'	'
Share-based compensation	5,412,451	'	452	5,441,166	'	'	-29,167	5,412,451	'
Net proceeds from issuance of common stock (in shares)	'	'	3,949,255	'	'	'	'	'	'
Net proceeds from issuance of common stock	21,517,422	'	3,949	21,513,473	'	'	'	21,517,422	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	'	'	16,369	'	'	'	'	'	'
Proceeds from Stock Options Exercised	86,658	'	16	86,642	'	'	'	86,658	'
Proceeds from warrant exercise (in shares)	'	'	401,215	'	'	'	'	'	'
Proceeds from exercise of warrants	2,126,291	'	402	2,125,889	'	'	'	2,126,291	'
Warrant Inducements (in shares)	'	'	0	'	'	'	'	'	'
Warrant Inducements	0	'	0	'	'	'	'	'	'
Stock Issued During Period, Value, Warrant Inducements	-62,014	'	'	-62,014	'	'	'	-62,014	'
Change in Ownership in Subsidiary	0	'	0	-111,680	'	'	'	-111,680	111,680
Ending Balance at Sep. 30, 2013	$35,134,395	$100	$21,194	$260,212,091	$0	($223,839,053)	($694,767)	$35,699,565	($565,170)
Ending Balance (shares) at Sep. 30, 2013	'	10,000	21,193,870	'	'	'	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:	'	'
Net loss	($26,766,572)	($51,025,744)
Loss from discontinued operations	0	27,260,584
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Common stock, stock options and warrants issued as payment for compensation, services rendered	5,412,451	5,471,166
Depreciation and amortization	1,197,801	1,160,596
Amortization of preferred stock discount and issuance cost	0	1,195,217
Changes in fair value of derivative liability	12,952	-46,910
Gain (Loss) on Sale of Property Plant Equipment	'	12,964
Bad debt (recovery) expense	-232,531	328,003
Deferred Income Taxes	492,325	0
Prepaid expenses and other current assets	-663,543	4,337
Accounts receivable	-108,363	-1,112,107
Inventory	583,659	199,700
Unearned revenues	-446,399	-368,510
Other assets	421	-187,123
Accounts payable, accrued expenses and other current liabilities	780,100	711,997
Net cash used in operating activities - continuing operations	-19,737,699	-16,395,830
Net cash provided by operating activities - discontinued operations	0	12,168,199
Net cash used in operating activities	-19,737,699	-4,227,631
Cash flows from investing activities:	'	'
Proceeds from Divestiture of Businesses	0	2,728,000
Acquisition of property and equipment	-948,644	-197,577
Net cash (used in) provided by investing activities - continuing operations	-948,644	2,530,423
Net cash used in investing activities - discontinued operations	0	-5,218,531
Net cash used in investing activities	-948,644	-2,688,108
Cash flows from financing activities:	'	'
Proceeds from Stock Options Exercised	86,658	0
Proceeds from exercise of warrants	2,126,291	5,925,931
Net proceeds from issuance of capital stock	21,517,422	12,160,227
Repayment of mortgage loan	-150,294	-141,353
Proceeds from notes payable	709,741	223,433
Repayment of notes payable	-332,713	-187,956
Repayment of preferred stock	0	-2,258,852
Payments of Dividends	'	-56,850
Payment for warrant inducement	0	-1,012,819
Change in warrant liabilities	62,014	43,716
Net cash provided by financing activities - continuing operations	23,895,091	15,620,864
Net cash used in financing activities - discontinued operations	0	-5,198,330
Net cash provided by financing activities	23,895,091	10,422,534
Impact of changes of foreign exchange rates	0	-72,136
Net increase in cash and cash equivalents	3,208,748	3,434,659
Cash and cash equivalents at beginning of period	13,737,452	12,745,432
Cash and cash equivalents at end of period	16,946,200	16,180,091
Less cash and cash equivalents of discontinued operations at end of period	0	10,789,480
Cash and cash equivalents of continuing operations at end of period	16,946,200	5,390,611
Supplemental Disclosure of Cash Flow Information:	'	'
Interest	202,800	1,655,600
Taxes	0	1,841,400
Capitalized interest	0	154,700
Common stock issued pursuant to the redemption of Convertible Redeemable Series E 7% Preferred Stock	0	1,026,600
Common stock issued in payment of dividends for the Convertible Redeemable Series E 7% Preferred Stock	$0	$175,700

The_Business

The Business	9 Months Ended
	Sep. 30, 2013
The Business [Abstract]	'
Nature of Operations [Text Block]	'
	The Business
	Overview
	NeoStem, Inc. (“we,” “NeoStem” or the “Company”) is a leader in the emerging cellular therapy industry. Cellular therapy addresses the process by which new cells are introduced into a tissue and administered to prevent or treat disease, or regenerate damaged or aged tissue. Modern cell-based therapies have progressed from the first recorded human to human blood transfusion 200 years ago through to the advanced cellular therapies of today including bone marrow and organ transplantation, tissue banking and reproductive in vitro fertilization and future therapies being investigated to treat cancer, cardiologic, neurologic, ophthalmic and orthopedic diseases among others. We anticipate that cellular therapies will have a large role in changing the natural history of the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society.
	Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization (“CDMO”) providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation.
	Progenitor Cell Therapy, LLC, our wholly owned subsidiary (“PCT”), is a leading CDMO in the cellular therapy industry. Since its inception, PCT has provided pre-clinical and clinical current Good Manufacturing Practice (“cGMP”) development and manufacturing services to over 100 clients advancing regenerative medicine product candidates through rigorous quality standards all the way through to human testing. PCT's core competencies in the cellular therapy industry include manufacturing of cell therapy-based products, product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery and consulting services. PCT has two cGMP, state-of-the art cell therapy research, development, and manufacturing facilities in New Jersey and California, serving the cell therapy community with integrated and regulatory compliant distribution capabilities. Expansion work currently in progress at PCT's New Jersey and California facilities is expected to be completed during the first quarter of 2014. The Company intends to pursue commercial expansion of our manufacturing operations both in the U.S. and internationally.
	Our wholly-owned subsidiary, Amorcyte, LLC (“Amorcyte”), is developing AMR-001 for the treatment of cardiovascular disease. AMR-001 represents Amorcyte's most clinically advanced therapeutic product candidate and enrollment for the Phase 2 PreSERVE clinical trial to investigate AMR-001's safety and efficacy in preserving heart function after a particular type of acute myocardial infarction (“AMI”) commenced in 2012. We are on track to complete patient enrollment for this study in 2013 with the first data readout expected six to eight months after the last patient is infused. If approved by the U.S. Food and Drug Administration ("FDA") and/or other worldwide regulatory agencies, AMR-001 would address a significant unmet medical need in the treatment of AMI, potentially improving the quality and longevity of life for those afflicted, and positioning the Company to capture a meaningful share of the worldwide AMI therapy market. Potential congestive heart failure and traumatic brain injury indications for AMR-001 are also being explored.
	Through our majority-owned subsidiary, Athelos Corporation (“Athelos”), we are collaborating with Becton-Dickinson and the University of California, San Francisco in early stage clinical development of a therapy that utilizes T-cells, to treat autoimmune and inflammatory conditions. We plan to file an Investigational New Drug Application ("IND") to investigate the clinical feasibility of nTreg-based therapeutics to prevent and/or treat steroid resistant asthma (preparing for Phase 1b/2a trial). Through INDs sponsored by UCSF we also plan to study nTreg-based therapeutics in prevention and/or treatment of type 1 diabetes (Phase 2 IND in preparation), and solid organ transplantation tolerance (Phase 1 IND submitted).
	Pre-clinical assets include our VSELTM (Very Small Embryonic Like) Technology platform. We expect to file an IND with the FDA to initiate a National Institutes of Health ("NIH") funded human clinical study to investigate the impact of VSELsTM in a tissue repair application. We are also working on a Department of Defense funded study of VSELsTM for the treatment of chronic wounds. Other preclinical work with VSELsTM includes exploring macular degeneration as a target indication.
	NeoStem's origins are in adult stem cell collection and storage and we believe that as new therapeutics are developed utilizing one's own stored cells (autologous), the market penetration rate for the collection and storage business may rise sharply from its current low single digits percentage level, allowing our developing network to scale rapidly if the demand grows.
	In 2011, we operated our business in three reportable segments: (i) Cell Therapy — United States; (ii) Regenerative Medicine — China; and (iii) Pharmaceutical Manufacturing — China. In 2012, we exited our operations in China. Effective March 31, 2012, we no longer operated in the Regenerative Medicine – China reportable segment, which was reported in discontinued operations in 2012 (see Note 14). On November 13, 2012, we completed the sale of our 51% interest in Suzhou Erye, which represented the operations in our Pharmaceutical Manufacturing - China segment, and is also reported in discontinued operations (see Note 14). As a result, we currently operate in a single reporting segment - Cell Therapy, which will focus on CDMO and cell therapy development programs.
	We believe that NeoStem is ideally positioned to be an integrated leader in the cell therapy industry. We have significant basic research and development capabilities, manufacturing facilities on both the east and west coast of the United States, the support of regulatory and logistical expertise and a talented and experienced clinical team. We believe this expertise will allow us to achieve our mission of becoming the premier cell therapy company.
	Basis of Presentation
	The accompanying unaudited Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“generally accepted accounting principles”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission for interim financial information. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, the accompanying Consolidated Financial Statements of the Company and its subsidiaries, which are unaudited, include all normal and recurring adjustments considered necessary to present fairly the Company’s financial position as of September 30, 2013 and the results of its operations and its cash flows for the periods presented. The unaudited consolidated financial statements herein should be read together with the historical consolidated financial statements of the Company for the years ended December 31, 2012 and 2011 included in our Annual Report on Form 10-K for the year ended December 31, 2012. Operating results for the nine months ended September 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013.
	Use of Estimates
	The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates.
	Principles of Consolidation
	The Consolidated Financial Statements include the accounts of NeoStem, Inc. and its wholly owned and partially owned subsidiaries and affiliates as listed below, as well as the operations of our former Regenerative Medicine - China segment through the deconsolidation date on March 31, 2012 (see Note 14), and the operations of our former Pharmaceutical Manufacturing - China reporting segment through November 13, 2012, representing the date which the segment was sold (see Note 14). These former segments are reported in discontinued operations.
	Entity	Percentage of Ownership	Location
	NeoStem, Inc.	Parent  Company	United States of America
	NeoStem Therapies, Inc.	100%	United States of America
	Stem Cell Technologies, Inc.	100%	United States of America
	Amorcyte, LLC	100%	United States of America
	Progenitor Cell Therapy, LLC (PCT)	100%	United States of America
	NeoStem Family Storage, LLC	100%	United States of America
	Athelos Corporation (1)	83.30%	United States of America
	PCT Allendale, LLC	100%	United States of America
	(1) Pursuant to the Stock Purchase Agreement signed in March 2011, our initial ownership in Athelos was 80.1%, and Becton Dickinson's ("BD") initial minority ownership was 19.9%. Per the Agreement, BD will be diluted based on new investment in Athelos by us (subject to certain anti-dilution provisions). As of September 30, 2013, BD's ownership interest in Athelos was decreased to 16.7%, and our ownership increased to 83.3%. As a result in the change in ownership, approximately $0.1 million was transferred from additional paid in capital to non-controlling interests.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Summary of Significant Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies [Text Block]	'
	Summary of Significant Accounting Policies
	In addition to the policies below, our significant accounting policies are described in Note 2 of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2012. There were no changes during the nine months ended September 30, 2013.
	Accounts Receivable
	Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts. The Company applies judgment in connection with establishing the allowance for doubtful accounts. Specifically, the Company analyzes the aging of accounts receivable balances, historical bad debts, customer concentration and credit-worthiness, current economic trends and changes in the Company’s customer payment terms. Significant changes in customer concentrations or payment terms, deterioration of customer credit-worthiness or weakening economic trends could have a significant impact on the collectability of the receivables and the Company’s operating results. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. Management regularly reviews the aging of receivables and changes in payment trends by its customers, and records a reserve when it believes collection of amounts due are at risk.
	Goodwill and Other Intangible Assets
	Goodwill is the excess of purchase price over the fair value of identified net assets of businesses acquired. The Company’s intangible assets with an indefinite life are related to in process research and development for AMR-001, the clinical candidate acquired in the Amorcyte acquisition, as the Company expects this research and development to provide the Company with substantial benefit for a period that extends beyond the foreseeable horizon. Amortized intangible assets consist of customer lists, manufacturing technology, and tradename, as well as patents and rights associated primarily with the VSELTM Technology. These intangible assets are amortized on a straight line basis over their respective useful lives.
	The Company reviews goodwill and indefinite-lived intangible assets at least annually for possible impairment. Goodwill and indefinite-lived intangible assets are reviewed for possible impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying value. The Company tests its goodwill and indefinite-lived intangible assets each year on December 31. The Company reviews the carrying value of goodwill and indefinite-lived intangible assets utilizing a discounted cash flow model, and, where appropriate, a market value approach is also utilized to supplement the discounted cash flow model. The Company makes assumptions regarding estimated future cash flows, discount rates, long-term growth rates and market values to determine each reporting unit’s estimated fair value. If these estimates or related assumptions change in the future, the Company may be required to record impairment charges.
	Revenue Recognition
	Clinical Services: The Company recognizes revenue for its (i) cell process development and (ii) cell manufacturing services based on the terms of individual contracts.
	Revenues associated with cell process development services generally contain multiple stages that do not have stand-alone values and are dependent upon one another, and are recognized as revenue on a completed contract basis. We recognize revenues for cell development services when all of the following conditions are met:
	•	persuasive evidence of an arrangement exists;
	•	delivery has occurred or the services have been rendered;
	•	the fee is fixed or determinable; and
	•	collectability is probable.
	The Company considers signed contracts as evidence of an arrangement. The Company assesses whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the payment terms are subject to refund or adjustment. The Company assesses cash collectability based on a number of factors, including past collection history with the client and the client's creditworthiness. If the Company determines that collectability is not reasonably assured, it defers revenue recognition until collectability becomes reasonably assured, which is generally upon receipt of the cash.
	Cell manufacturing services are generally distinct arrangements whereby the Company is paid for time and materials or for fixed monthly amounts. Revenue is recognized when efforts are expended or contractual terms have been met.
	Some client agreements include multiple elements, comprised of cell process development and cell manufacturing services.  The Company believes that cell process development and cell manufacturing services each have stand-alone value because these services can be provided separately by other companies. In accordance with ASC Update No. 2009-13, “Revenue Recognition (Topic 605): Multiple-Deliverable Revenue Arrangements,” the Company (1) separates deliverables into separate units of accounting when deliverables are sold in a bundled arrangement and (2) allocates the arrangement's consideration to each unit in the arrangement based on its relative selling price.
	Clinical Services Reimbursements: The Company separately charges the customers for the expenses associated with certain consumable resources (reimbursable expenses) that are specified in each clinical services contract. On a monthly basis, the Company bills customers for reimbursable expenses and immediately recognizes these billings as revenue, as the revenue is deemed earned as reimbursable expenses are incurred. For the three months ended September 30, 2013 and 2012, clinical services reimbursements were $0.6 million and $0.9 million, respectively. For the nine months ended September 30, 2013 and 2012, clinical services reimbursements were $1.4 million and $2.9 million, respectively.
	Processing and Storage Services: The Company recognizes revenue related to the collection and cryopreservation of cord blood and autologous adult stem cells when the cryopreservation process is completed which is approximately twenty-four hours after cells have been collected. Revenue related to advance payments of storage fees is recognized ratably over the period covered by the advance payments.

Cash_and_Cash_Equivalents

Cash and Cash Equivalents	9 Months Ended
	Sep. 30, 2013
Cash and Cash Equivalents [Abstract]	'
Cash and Cash Equivalents [Text Block]	'
	Cash and Cash Equivalents
	As of September 30, 2013 and December 31, 2012, the Company had cash and cash equivalents of approximately $16.9 million and $13.7 million, respectively, including bank deposits of approximately $0.7 million and $0.8 million, respectively, covered by the Federal Deposit Insurance Corporation.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2013
Inventories [Abstract]	'
Inventory Disclosure [Text Block]	'
	Inventories
	Inventories, representing work in process for costs incurred on projects at PCT that have not been completed, were $0.5 million and $1.1 million as of September 30, 2013 and December 31, 2012, respectively. The Company also has deferred revenue of approximately $0.7 million and $1.2 million of advance billings received as of September 30, 2013 and December 31, 2012, respectively, related to these contracts.

Loss_Per_Share

Loss Per Share	9 Months Ended
	Sep. 30, 2013
Loss Per Share [Abstract]	'
Loss Per Share [Text Block]	'
	Loss Per Share
	For three and nine months ended September 30, 2013 and 2012, the Company incurred net losses and therefore no common stock equivalents were utilized in the calculation of loss per share. At September 30, 2013 and 2012, the Company excluded the following potentially dilutive securities:
		September 30,
		2013	2012
	Stock Options	2,840,668	2,238,964
	Warrants	5,054,302	5,631,418
	Series E Preferred Stock, Common stock equivalents	—	236,480
	Restricted Shares	92,000	23,200

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2013
Fair Value Measurements [Abstract]	'
Fair Value Disclosures [Text Block]	'
	Fair Value Measurements
	Fair value of financial assets and liabilities that are being measured and reported are defined as the exchange price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the principal market at the measurement date (exit price). The Company is required to classify fair value measurements in one of the following categories:
	Level 1 inputs are defined as quoted prices (unadjusted) in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
	Level 2 inputs are defined as inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly.
	Level 3 inputs are defined as unobservable inputs for the assets or liabilities. Financial assets and liabilities are classified based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels.
	The Company determined the fair value of the warrant derivative liabilities to be level 3 inputs. These inputs require material subjectivity because value is derived through the use of a lattice model that values the derivatives based on probability weighted discounted cash flows.
	The Company also determined the fair value of contingent consideration, initially recognized on October 17, 2011 in connection with the Company's acquisition of Amorcyte, to be level 3 inputs. The fair value of contingent consideration obligations is based on a discounted cash flow model using a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity based on our own assumptions and experience. The value of our contingent consideration was initially calculated using a discount rate of 30%. We base the timing to complete the development and approval of this product on the current development stage of the product and the inherent difficulties and uncertainties in developing a product candidate, such as obtaining U.S. Food and Drug Administration (FDA) and other regulatory approvals. In determining the probability of regulatory approval and commercial success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period. Changes in the fair value of the contingent consideration obligations are recorded in our consolidated statement of operations.
	The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2013, and December 31, 2012 (in thousands):
		September 30, 2013
		Fair Value Measurements Using Fair Value Hierarchy
		Level 1		Level 2		Level 3
	Warrant derivative liabilities	$	—	$	—	$	114.1
	Contingent consideration	—		—		7,550.00
		December 31, 2012
		Fair Value Measurements Using Fair Value Hierarchy
		Level 1		Level 2		Level 3
	Warrant derivative liabilities	$	—	$	—	$	101.2
	Contingent consideration	—		—		7,550.00
	For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the three and nine months ended September 30, 2013 by type of instrument (in thousands):
		Three Months Ended				Nine Months Ended
		September 30, 2013				September 30, 2013
		Warrants		Contingent Consideration		Warrants		Contingent Consideration
	Beginning liability balance	$	32.6	$	7,550.00	$	101.2	$	7,550.00
	Change in fair value recorded in earnings	81.5		—		12.9		—
	Ending liability balance	$	114.1	$	7,550.00	$	114.1	$	7,550.00
	Some of the Company’s financial instruments are not measured at fair value on a recurring basis, but are recorded at amounts that approximate fair value due to their liquid or short-term nature, such as cash and cash equivalents, accounts receivable, accounts payable and notes payable, and long-term notes payable and mortgages.

Goodwill_and_Other_Intangible_

Goodwill and Other Intangible Assets	9 Months Ended
	Sep. 30, 2013
Goodwill and Other Intangible Assets [Abstract]	'
Goodwill and Intangible Assets [Text Block]	'
	Goodwill and Other Intangible Assets
	The Company's goodwill was $11.1 million as of September 30, 2013 and December 31, 2012.
	The Company's intangible assets and related accumulated amortization as of September 30, 2013 and December 31, 2012 consisted of the following (in thousands):
				30-Sep-13												31-Dec-12
		Useful Life		Gross				Accumulated Amortization				Net				Gross		Accumulated Amortization			Net
	Customer list	10 years		$	1,000.00			$	(270.1	)		$	729.9			$	1,000.00	$	(195.1	)	$	804.9
	Manufacturing technology	10 years		3,900.00				(1,053.4		)		2,846.60				3,900.00		(760.9		)	3,139.10
	Tradename	10 years		800				(216.1		)		583.9				800		(156.1		)	643.9
	In process R&D	Indefinite		9,400.00				—				9,400.00				9,400.00		—			9,400.00
	VSEL patent rights	19 years		669				(202.5		)		466.5				669		(176.1		)	492.9
	Total Intangible Assets			$	15,769.00			$	(1,742.1	)		$	14,026.90			$	15,769.00	$	(1,288.2	)	$	14,480.80
	Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):
		Three Months Ended September 30,								Nine Months Ended September 30,
		2013				2012				2013				2012
	Cost of revenue	$	97.5			$	97.5			$	292.5			$	292.5
	Research and development	8.8				8.8				26.4				26.4
	Selling, general and administrative	45				45				135				135
	Total	$	151.3			$	151.3			$	453.9			$	453.9
	Estimated intangible amortization expense on an annual basis for the succeeding five years is as follow (in thousands):
	2013	$	151.3
	2014	605.2
	2015	605.2
	2016	605.2
	2017	605.2
	Thereafter	11,454.80
		$	14,026.90

Accrued_Liabilities

Accrued Liabilities	9 Months Ended
	Sep. 30, 2013
Accrued Liabilities [Abstract]	'
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	'
	Accrued Liabilities
	Accrued liabilities as of September 30, 2013 and December 31, 2012 were as follows (in thousands):
		September 30, 2013		31-Dec-12
	Salaries, employee benefits and related taxes	$	920.8	$	1,597.20
	Professional fees	654.9		606.6
	Other	656.1		81
		$	2,231.80	$	2,284.80

Debt

Debt	9 Months Ended
	Sep. 30, 2013
Debt [Abstract]	'
Debt Disclosure [Text Block]	'
	Debt
	Notes Payable
	As of September 30, 2013 and December 31, 2012, the Company had notes payable of approximately $0.8 million and $0.4 million, respectively. The notes relate to certain insurance policies and equipment financings, require monthly payments, and mature within one to three years.
	Mortgages Payable
	On October 31, 2007, PCT issued a note to borrow $3.1 million (the “Note”) in connection with its $3.8 million purchase of condominium units in an existing building in Allendale, New Jersey (the “Property”) that PCT uses as a laboratory and stem cell processing facility. The Note is payable in 239 consecutive monthly payments of principal and interest, based on a 20 year amortization schedule; and one final payment of all outstanding principal plus accrued interest then due. The current monthly installment is $20,766, which includes interest at an initial rate of 5.00%; the interest rate and monthly installments payments are subject to adjustment on October 1, 2017. On that date, upon prior written notice, the lender has the option to declare the entire outstanding principal balance, together with all outstanding interest, due and payable in full. The Note is secured by substantially all of the assets of PCT, including a first mortgage on the Property and assignment of an amount approximately equal to eighteen months debt service held in escrow. The Note matures on October 1, 2027 if not called by the lender on October 1, 2017. The note is subject to certain debt service coverage and total debt to tangible net worth financial covenant ratios measured semi-annually. PCT was not in compliance with such covenants at the measurement date of December 31, 2012, and June 30, 2013, and obtained a covenant waiver letter from the lender for each period. The outstanding balance was approximately $2.5 million at September 30, 2013, and $2.6 million at December 31, 2012, respectively, of which $0.1 million is payable within twelve months as of September 30, 2013. The mortgage is classified as a current liability.
	On December 6, 2010 PCT Allendale, a wholly-owned subsidiary of PCT, entered into a note for a second mortgage in the amount of $1 million on the Allendale Property with TD Bank, N.A. This loan is guaranteed by PCT, DomaniCell (a wholly-owned subsidiary of PCT, now known as NeoStem Family Storage, LLC), Northern New Jersey Cancer Associates (“NNJCA”) and certain partners of NNJCA and is subject to an annual financial covenant starting December 31, 2011. PCT was not in compliance with such covenants at the measurement date of December 31, 2012, and obtained a covenant waiver letter from the lender. The loan is for 124 months at a fixed rate of 6% for the first 64 months. The loan is callable for a certain period prior to the interest reset date. The outstanding balance was approximately $0.8 million at September 30, 2013, and $0.8 million at December 31, 2012, respectively, of which $0.1 million is payable within twelve months as of September 30, 2013. The mortgage is classified as a current liability.

Preferred_Stock

Preferred Stock	9 Months Ended
	Sep. 30, 2013
Preferred Stock [Abstract]	'
Preferred Stock [Text Block]	'
	Preferred Stock
	Convertible Redeemable Series E 7% Preferred Stock
	On November 19, 2010, the Company sold 10,582,011 Preferred Offering Units consisting of (i) 10,582,011 shares (“Preferred Shares”) of Series E 7% Senior Convertible Preferred Stock (the “Series E Preferred Stock”), par value $0.01 per share, of the Company, (ii) Class E Warrants to purchase an aggregate of 132,249 shares of Common Stock, adjusted to an aggregate of 199,031 shares as of September 30, 2013; and (iii) an aggregate of 16,442 shares of Common Stock. Each Preferred Offering Unit was priced at $0.945 and total gross and net proceeds received by the Company were $10.0 million and $8.9 million, respectively.
	Monthly dividend and principal payments began in March 2011, and continued each month thereafter with the final payment due in May 2013. In October 2012, the Company completed the redemption of all 2,351,558 Series E Preferred Stock shares then remaining outstanding , for an aggregate cash redemption price of approximately $3.4 million, $2.5 million of which was funded by money placed into escrow when the Series E Preferred stock was issued in November 2010. The cash redemption included the repayment of $3.1 million outstanding principal, an additional early redemption premium of $0.2 million, which was included in dividends, and $36,000 of accrued interest.
	The Company recorded the fair value of the warrants as a long-term derivative liability. The fair values of the warrant derivatives as of September 30, 2013 and December 31, 2012 were $114,100 and $101,200, respectively. The Company reports changes in the fair value of the warrant derivative in earnings within other income (expense), net (see Note 6).

Shareholders_Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2013
Shareholdersb Equity [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	Shareholders' Equity
	Reverse Stock Split
	On June 28, 2013, pursuant to prior shareholder authorization, the Company’s board of directors unanimously approved a 1-for-10 reverse stock split of the Company’s common stock, which the Company effected on July 16, 2013. All share and per share amounts of common stock, options and warrants in the accompanying financial statements have been restated for all periods to give retroactive effect to the reverse stock split. The shares of common stock retained a par value of $0.001 per share. Accordingly, the stockholders’ deficit reflects the reverse stock split by reclassifying from “common stock” to “Additional paid-in capital” an amount equal to the par value of the decreased shares resulting from the reverse stock split.
	Equity Issuances
	In September 2011, the Company entered into a Common Stock Purchase Agreement, (the “Purchase Agreement”) with Aspire Capital Fund, LLC, an Illinois limited liability company (“Aspire Capital”), which provides that, subject to certain terms and conditions, Aspire Capital is committed to purchase up to an aggregate of $20.0 million worth of shares of the Company’s common stock over the term of the Purchase Agreement (initially 24 months). At the Company’s discretion, it may present Aspire Capital with purchase notices under the Purchase Agreement from time to time, to purchase the Company’s Common Stock, provided certain price and other requirements are met. The purchase price for the shares of stock is based upon one of two formulas set forth in the Purchase Agreement depending on the type of purchase notice we submit to Aspire Capital from time to time, and is based on market prices of the Company’s common stock (in the case of regular purchases) or a discount of 5% applied to volume weighted average prices (in the case of VWAP purchases), in each case as determined by parameters defined in the Purchase Agreement. The Company and Aspire Capital shall not effect any sales under the Purchase Agreement on any date where the closing sales price is less than 75% of the closing sales price on the business day immediately preceding the date of the Purchase Agreement. The Company’s net proceeds will depend on the purchase price and the frequency of the Company’s sales of shares to Aspire Capital; provided, however, that the maximum aggregate proceeds from sales of shares is $20.0 million. The Company’s delivery of purchase notices will be made subject to market conditions, in light of the Company’s capital needs from time to time and under the limitations contained in the Purchase Agreement. As consideration for entering into the Purchase Agreement, effective September 30, 2011, we issued 99,010 shares of our Common Stock to Aspire Capital (the “Commitment Shares”). The issuance of shares of common stock to Aspire Capital pursuant to the Purchase Agreement, including the Commitment Shares, and the sale of those shares from time to time by Aspire Capital to the public, are covered by an effective shelf registration statement on Form S-3.
	In August 2012, the Company and Aspire entered into an amendment to the Purchase Agreement providing for an extension of the term of the Purchase Agreement until September 30, 2015. Pursuant to the amendment, we agreed to issue to Aspire a five-year warrant to purchase up to 161,290 shares of our common stock at an exercise price of $6.00 per share (the closing price of our common stock on the date the amendment was executed).
	During the nine months ended September 30, 2013, the Company issued 1,639,659 shares of Common Stock under the provisions of its equity line of credit with Aspire for gross proceeds of approximately $11.1 million. As of September 30, 2013, the remaining amount available to the Company under the Purchase Agreement was $5.6 million.
	In the second quarter of 2013, the Company completed an underwritten offering of 2.0 million shares of the Company's common stock, at a public offering price of $5.00 per share.  The underwriters also exercised their entire over-allotment option of 0.3 million shares. The Company received gross proceeds of $11.5 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company.
	Option Exercises
	During the nine months ended ended September 30, 2013, option holders exercised an aggregate of 16,369 options at exercise prices between $4.90 and $5.90 per share for gross proceeds of approximately $0.1 million.
	Warrant Exercises
	To raise capital on terms that we deemed favorable, during the nine months ended September 30, 2013, the Board authorized certain inducements to warrant holders to exercise outstanding common stock purchase warrants significantly before their expiration dates. The Company determined in each instance that such inducements were modifications of equity instruments, and an incremental fair value of the inducement was determined using the Black-Scholes option pricing model.
	During the nine months ended ended September 30, 2013, warrant holders exercised an aggregate of 401,215 warrants at exercise prices between $5.10 and $7.40 per share for gross proceeds of approximately $2.1 million. As an inducement to exercise, we paid certain warrant holders $0.30 per share upon each exercise. The incremental fair value of the inducement recorded was $0.
	Stock Options and Warrants
	The following table summarizes the activity for stock options and warrants for the nine months ended September 30, 2013:
		Stock Options				Warrants
		Shares			Weighted Average Exercise Price	Shares		Weighted Average Exercise Price
	Outstanding at December 31, 2012	2,168,668			$12.85	5,528,761		$15.65
	Changes during the Year:
	Granted	895,418			7.06	42,835		6.28
	Exercised	(16,369	)		5.29	(401,215	)	5.3
	Forfeited	(86,212	)		5.51	—		—
	Expired	(120,837	)		16.99	(116,079	)	20.61
	Outstanding at September 30, 2013	2,840,668			$11.12	5,054,302		$16.26
	During the nine months ended September 30, 2013 and 2012, the Company issued warrants for services as follows ($ in thousands, except share data):
			Nine Months Ended September 30,
			2013			2012
	Number of Common Stock Purchase Warrants Issued		20,407			38,500
	Value of Common Stock Purchase Warrants Issued		$	70.5		$	166.2
	Restricted Stock
	During the nine months ended September 30, 2013 and 2012, the Company issued restricted stock for services as follows ($ in thousands, except share data):
			Nine Months Ended September 30,
			2013			2012
	Number of Restricted Stock Issued		452,454			269,727
	Value of Restricted Stock Issued		$	2,967.70		$	1,438.60
	The weighted average estimated fair value of restricted stock issued for services in the nine months ended September 30, 2013 and 2012 was $6.56 and $5.33 per share, respectively. The fair value of the restricted stock was determined using the Company’s closing stock price on the date of issuance. The vesting terms of restricted stock issuances are generally within one year.

ShareBased_Compensation_Notes

Share-Based Compensation (Notes)	9 Months Ended
	Sep. 30, 2013
Share-based Compensation [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	Share-Based Compensation
	Share-based Compensation
	We utilize share-based compensation in the form of stock options, warrants and restricted stock.  The following table summarizes the components of share-based compensation expense for the three and nine months ended September 30, 2013 and 2012 (in thousands):
		Three Months Ended September 30,				Nine Months Ended September 30,
		2013		2012		2013		2012
	Cost of goods sold	$	88.8	$	19.8	$	233.7	$	120.1
	Research and development	319.9		102.2		667		362.4
	Selling, general and administrative	1,718.90		1,794.20		4,511.80		4,988.70
	Total share-based compensation expense	$	2,127.60	$	1,916.20	$	5,412.50	$	5,471.20
	Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at September 30, 2013 were as follows (dollars in thousands):
		Stock Options		Warrants		Restricted Stock
	Unrecognized compensation cost	$	3,101.80	$	16.2	$	588.7
	Expected weighted-average period in years of compensation cost to be recognized	4.07		0.24		0.57
	Total fair value of shares vested and the weighted average estimated fair values of shares granted for the nine months ended September 30, 2013 and 2012 were as follows (dollars in thousands):
		Stock Options				Warrants
		Nine Months Ended September 30,				Nine Months Ended September 30,
		2013		2012		2013		2012
	Total fair value of shares vested	$	2,470.00	$	3,637.80	$	123	$	121.6
	Weighted average estimated fair value of shares granted	$	4.3	$	3.63	$	3.45	$	4.32

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2013
Income Taxes [Abstract]	'
Income Tax Disclosure [Text Block]	'
	Income Taxes
	The Tax Reform Act of 1986 enacted a complex set of rules limiting the utilization of net operating loss carryforwards (“NOL”) to offset future taxable income following a corporate ownership change. The Company’s ability to utilize its NOL carryforwards is limited following a change in ownership in excess of fifty percentage points during any three-year period.
	Since the year 2000, the Company has had several changes in ownership which has resulted in a limitation on the Company’s ability to apply net operating losses to future taxable income. As of December 31, 2012, the Company has lost $26.0 million or $8.8 million in tax benefits, of net operating losses applicable to Federal income taxes which expired due to these limitations and expiration of net operating loss carryforwards. At December 31, 2012, the Company had net operating loss carryforwards of approximately $69.7 million applicable to future Federal income taxes. The tax loss carryforwards are subject to annual limitations and expire at various dates through 2030. The Company has recorded a full valuation allowance against its net deferred tax asset because it is more likely than not that such deferred tax assets will not be realized.
	Deferred tax liabilities were $4.1 million and $3.6 million as of September 30, 2013 and December 31, 2012, and relate to the taxable temporary differences on the goodwill recognized in the PCT acquisition in 2011, and the in-process R&D intangible asset recognized in the Amorcyte acquisition in 2011. The taxable temporary difference associated with the goodwill, which is tax deductible and will be amortized over 15 years, will continue to increase the deferred tax liability balance over the amortization period, with an associated charge to the tax provision in each period. The deferred tax liabilities will only reverse when these indefinite-lived assets are sold, impaired, or reclassified from an indefinite-lived asset to a finite-lived asset.
	As of September 30, 2013, management does not believe the Company has any material uncertain tax positions that would require it to measure and reflect the potential lack of sustainability of a position on audit in its financial statements. The Company will continue to evaluate its uncertain tax positions in future periods to determine if measurement and recognition in its financial statements is necessary. The Company does not believe there will be any material changes in its unrecognized tax positions over the next year.

Discontinued_Operations

Discontinued Operations	9 Months Ended
	Sep. 30, 2013
Discontinued Operations [Abstract]	'
Discontinued Operations [Text Block]	'
	Discontinued Operations
	Regenerative Medicine - China segment
	In 2009, the Company operated its Regenerative Medicine-China business in the People’s Republic of China (“China” or “PRC”) through its subsidiary, a wholly foreign owned entity (“WFOE”) and entered into contractual arrangements with certain variable interest entities (“VIEs”). Foreign companies have commonly used VIE structures to operate in the PRC, and while such structures are not uncommon, they had drawn greater scrutiny from the local Chinese business community in the PRC who urged the PRC State Council to clamp down on these structures. In addition, in December 2011, China’s Ministry of Health announced its intention to more tightly regulate stem cell clinical trials and stem cell therapeutic treatments in the PRC, which created uncertainty regarding the ultimate regulatory environment in the PRC. Accordingly, the Company took steps to restrict, and ultimately eliminate, its regenerative medicine business in the PRC. As a result of these steps, the Company discontinued its operations in its Regenerative Medicine-China business. The Company determined that any liability arising from the activities of the WFOE and the VIEs will likely be limited to the net assets currently held by each entity. As of March 31, 2012, the Company recognized the following loss on exit of the Regenerative Medicine-China business (in thousands):
	Cash	$	195.1
	Prepaid expenses and other current assets	14.9
	Property, plant and equipment, net	1,023.70
	Other Assets	330.5
	Accounts payable	(177.1		)
	Accrued liabilities	(79.2		)
	Accumulated comprehensive income	(169.9		)
	Loss on exit of segment	$	1,138.00
	The operations and cash flows of the Regenerative Medicine - China business were eliminated from ongoing operations as a result of our exit decision, and the Company will not have continuing involvement in this business going forward. The operating results of the Regenerative Medicine – China business for the nine months ended September 30, 2012, which are included in discontinued operations, were as follows (in thousands):
		Nine Months Ended September 30, 2012
	Revenue	$	52.3
	Cost of revenues	(30.6		)
	Research and development	(103.3		)
	Selling, general, and administrative	(497.3		)
	Other income (expense)	(6.8		)
	Loss on exit of segment	(1,138.0		)
	Loss from discontinued operations	$	(1,723.7	)
	Pharmaceutical Manufacturing - China segment
	On November 13, 2012, the Company completed the divestiture (the “Erye Sale”) of our 51% interest (the “Erye Interest”) in Suzhou Erye Pharmaceuticals Company Ltd., a Sino-foreign equity joint venture with limited liability organized under the laws of the PRC primarily engaged in the manufacture of generic antibiotics (“Erye”), to Suzhou Erye Economy & Trading Co., Ltd., a limited liability company organized under the laws of the PRC (“EET”), and Highacheive Holdings Limited, a limited liability company organized under the laws of the British Virgin Islands (“Highacheive” and together with EET, each a “Purchaser” and collectively the “Purchasers”). The Erye Sale was consummated pursuant to the terms and conditions of the Equity Purchase Agreement, dated as of June 18, 2012 (as amended, the “Equity Purchase Agreement”), by and among our Company, China Biopharmaceuticals Holdings, Inc., a wholly-owned subsidiary of NeoStem (“CBH”), EET, Highacheive, Fullbright Finance Limited, a limited liability company organized under the laws of the British Virgin Islands (“Fullbright”), and Erye. Pursuant to the Equity Purchase Agreement, the aggregate purchase price paid to the Company by the Purchasers for the Erye Interest consisted of (i) approximately $12.3 million in cash, (ii) the return to the Company of 104,000 shares of NeoStem common stock and (iii) the cancellation of 117,000 options and 64,000 warrants to purchase our common stock. The fair value of the shares was based on the Company's closing price on the date of sale, and was recorded as Treasury Stock in our balance sheet. The fair values of the canceled options and warrants were based on the Black-Scholes values on the date of sale, and were recorded against Additional Paid in Capital in the accompanying balance sheet.  The Company recognized the following loss on the date of sale of its 51% interest in Erye on November 13, 2012 (in thousands):
	Fair value of consideration received	$	13,397.90
	Carrying value of segment non-controlling interest	6,015.00
	Carrying value of segment accumulated comprehensive income	4,387.40
		$	23,800.30
	Less carrying amount of assets and liabilities sold:
	Cash	$	8,457.50
	Restricted Cash	2,918.10
	Accounts Receivable	6,130.20
	Inventories	15,077.70
	Prepaid expenses and other current assets	957.8
	Property, plant and equipment, net	38,102.00
	Other assets	5,946.30
	Accounts payable	(9,604.8		)
	Accrued liabilities	(2,008.8		)
	Bank loans	(15,133.5		)
	Notes payable	(6,599.3		)
	Other liabilities	(9,166.8		)
	Amount due related party	(7,859.7		)
		$	(27,216.7	)
	Loss on exit of segment	$	(3,416.4	)
	The operations and cash flows of the Pharmaceutical Manufacturing - China business were eliminated from ongoing operations with the sale of the Company's Erye Interest. The operating results of the Pharmaceutical Manufacturing - China business for the three and nine months ended September 30, 2012, including the estimated asset impairments based on the definitive agreement purchase price as of September 30, 2012, were as follows (in thousands):
		Three Months Ended September 30, 2012			Nine Months Ended September 30, 2012
	Revenue	$	20,036.40		$	57,254.70
	Cost of revenues	(11,551.5		)	(37,131.5		)
	Research and development	(611.8		)	(2,231.5		)
	Selling, general, and administrative	(3,514.7		)	(9,714.8		)
	Other expense	(0.9		)	(1,008.3		)
	Provision for income taxes	(1,029.9		)	(1,535.4		)
	Asset impairments	(3,175.5		)	(31,170.1		)
	Loss on sale of segment	—			—
	Loss from discontinued operations	$	152.1		$	(25,536.9	)

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions [Text Block]	'
	Related Party Transactions
	On November 13, 2012, we and our subsidiary, CBH, sold our 51% ownership interest in Erye to Fullbright and EET (see Note 14). EET was prior to the sale the holder of the minority 49% ownership interest in Erye, and was a party along with our subsidiary CBH to the Joint Venture Agreement which had governed the ownership of the respective interests in Erye. Fullbright is an affiliate of EET. Mr. Shi Mingsheng (a former member of our Board of Directors, and Chairman of the Board of Erye) and Madam Zhang Jian (the General Manager of Erye, and formerly our Vice President of Pharmaceutical Operations) are the principal equity holders of each of EET and Fullbright. Fullbright assigned all its rights and obligations under the Equity Purchase Agreement (except for its obligations in respect of the return of certain NeoStem securities held by it as part of the purchase price, and its obligations in respect of closing deliverables) to Highacheive. As a result of the assignment, the Purchasers of our Erye Interest were EET and Highacheive.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies [Abstract]	'
Commitments and Contingencies [Text Block]	'
	Commitments and Contingencies
	Lease Commitments
	The Company leases offices, of which certain have escalation clauses and renewal options, and also leases equipment under certain noncancelable operating leases that expire from time to time through 2017.
	A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of September 30, 2013 are as follows (in thousands):
	Years ended	Operating Leases
	2013	$	223.1
	2014	900.9
	2015	726.7
	2016	568.6
	2017	294.7
	Total minimum lease payments	$	2,714.00
	Expense incurred under operating leases was approximately $0.3 million and $0.4 million for the three months ended September 30, 2013 and 2012, respectively, and $0.9 million and $1.2 million for the nine months ended September 30, 2013 and 2012, respectively.
	Contingencies
	Under license agreements with third parties the Company is typically required to pay maintenance fees, make milestone payments and/or pay other fees and expenses and pay royalties upon commercialization of products. The Company also sponsors research at various academic institutions, which research agreements generally provide us with an option to license new technology discovered during the course of the sponsored research.
	In connection with the issuance to investors and service providers of many of the shares of the Company’s common stock and warrants to purchase common stock previously disclosed and described herein, the Company granted the holders registration rights providing for the registration of such shares of common stock and shares of common stock underlying warrants on a registration statement to be filed with the Securities and Exchange Commission (“SEC”) so as to permit the resale of those shares. Certain of the registration rights agreements provided for penalties for failure to file or failure to obtain an effective registration statement. With respect to satisfying its obligations to the holders of these registration rights, the Company has been in various situations. The Company had previously filed a registration statement as required for some of the holders, and in May 2011 filed a registration statement for all of the holders (except for holders whose shares of Common Stock were currently salable under Rule 144 of the Securities Act or who waived certain rights); such registration statement was declared effective by the SEC on September 30, 2011. The Company has certain obligations to maintain the effectiveness of this registration statement. Certain holders who had outstanding registration rights had previously waived their registration rights or were subject to lock-up agreements. No holder has yet asserted any claim against the Company with respect to a failure to satisfy any registration obligations. Were someone to assert a claim against the Company for breach of registration obligations, the Company believes it has several defenses that would result in relieving it from some or any liability, although no assurances can be given. The Company also notes that damage claims may be limited, as (i) most shares of Common Stock as to which registration rights attached are either now registered or currently salable under Rule 144 of the Securities Act or are otherwise currently subject to other restrictions on sale and (ii) the shares of Common Stock underlying warrants with registration rights are now registered, and during much of the relevant periods the warrants with registration rights generally have been out of the money, were subject to lock-up agreements and/or the underlying shares of Common Stock were otherwise subject to restrictions on resale. Accordingly, were holders to assert claims against the Company based on breach of the Company’s obligation to register, the Company believes that the Company’s maximum exposure would not be material.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	Subsequent Events
	Public Offering
	On October 3, 2013, the Company entered into an Underwriting Agreement (the “Underwriting Agreement”) with Aegis Capital Corp. (“Aegis”), providing for the offer and sale in a firm commitment underwritten public offering (the “Offering”) of 5,000,000 shares of the Company's common stock, par value $0.001 per share at a public offering price of $7.00 per share.  The underwriter also exercised its entire over-allotment option of 750,000 shares in accordance with the Underwriting Agreement. The Company received gross proceeds of approximately $40.3 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company. The Offering closed on October 9, 2013.
	Option and Warrant Exercises
	Subsequent to September 30, 2013, warrant holders exercised an aggregate of 161,951 warrants at exercise prices between $5.10 and $7.00 per share for gross proceeds of approximately $0.9 million, and option holders exercised an aggregate of 15,000 options at exercise prices between $4.00 and $4.40 per share, for gross proceeds of approximately $0.1 million.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2013
Summary of Significant Accounting Policies [Abstract]	'
Receivables, Policy [Policy Text Block]	'
	Accounts Receivable
	Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts. The Company applies judgment in connection with establishing the allowance for doubtful accounts. Specifically, the Company analyzes the aging of accounts receivable balances, historical bad debts, customer concentration and credit-worthiness, current economic trends and changes in the Company’s customer payment terms. Significant changes in customer concentrations or payment terms, deterioration of customer credit-worthiness or weakening economic trends could have a significant impact on the collectability of the receivables and the Company’s operating results. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. Management regularly reviews the aging of receivables and changes in payment trends by its customers, and records a reserve when it believes collection of amounts due are at risk.
Goodwill and Intangible Assets, Policy [Policy Text Block]	'
	Goodwill and Other Intangible Assets
	Goodwill is the excess of purchase price over the fair value of identified net assets of businesses acquired. The Company’s intangible assets with an indefinite life are related to in process research and development for AMR-001, the clinical candidate acquired in the Amorcyte acquisition, as the Company expects this research and development to provide the Company with substantial benefit for a period that extends beyond the foreseeable horizon. Amortized intangible assets consist of customer lists, manufacturing technology, and tradename, as well as patents and rights associated primarily with the VSELTM Technology. These intangible assets are amortized on a straight line basis over their respective useful lives.
	The Company reviews goodwill and indefinite-lived intangible assets at least annually for possible impairment. Goodwill and indefinite-lived intangible assets are reviewed for possible impairment between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of the reporting unit below its carrying value. The Company tests its goodwill and indefinite-lived intangible assets each year on December 31. The Company reviews the carrying value of goodwill and indefinite-lived intangible assets utilizing a discounted cash flow model, and, where appropriate, a market value approach is also utilized to supplement the discounted cash flow model. The Company makes assumptions regarding estimated future cash flows, discount rates, long-term growth rates and market values to determine each reporting unit’s estimated fair value. If these estimates or related assumptions change in the future, the Company may be required to record impairment charges.
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition
	Clinical Services: The Company recognizes revenue for its (i) cell process development and (ii) cell manufacturing services based on the terms of individual contracts.
	Revenues associated with cell process development services generally contain multiple stages that do not have stand-alone values and are dependent upon one another, and are recognized as revenue on a completed contract basis. We recognize revenues for cell development services when all of the following conditions are met:
	•	persuasive evidence of an arrangement exists;
	•	delivery has occurred or the services have been rendered;
	•	the fee is fixed or determinable; and
	•	collectability is probable.
	The Company considers signed contracts as evidence of an arrangement. The Company assesses whether the fee is fixed or determinable based on the payment terms associated with the transaction and whether the payment terms are subject to refund or adjustment. The Company assesses cash collectability based on a number of factors, including past collection history with the client and the client's creditworthiness. If the Company determines that collectability is not reasonably assured, it defers revenue recognition until collectability becomes reasonably assured, which is generally upon receipt of the cash.
	Cell manufacturing services are generally distinct arrangements whereby the Company is paid for time and materials or for fixed monthly amounts. Revenue is recognized when efforts are expended or contractual terms have been met.
	Some client agreements include multiple elements, comprised of cell process development and cell manufacturing services.  The Company believes that cell process development and cell manufacturing services each have stand-alone value because these services can be provided separately by other companies. In accordance with ASC Update No. 2009-13, “Revenue Recognition (Topic 605): Multiple-Deliverable Revenue Arrangements,” the Company (1) separates deliverables into separate units of accounting when deliverables are sold in a bundled arrangement and (2) allocates the arrangement's consideration to each unit in the arrangement based on its relative selling price.
	Clinical Services Reimbursements: The Company separately charges the customers for the expenses associated with certain consumable resources (reimbursable expenses) that are specified in each clinical services contract. On a monthly basis, the Company bills customers for reimbursable expenses and immediately recognizes these billings as revenue, as the revenue is deemed earned as reimbursable expenses are incurred. For the three months ended September 30, 2013 and 2012, clinical services reimbursements were $0.6 million and $0.9 million, respectively. For the nine months ended September 30, 2013 and 2012, clinical services reimbursements were $1.4 million and $2.9 million, respectively.
	Processing and Storage Services: The Company recognizes revenue related to the collection and cryopreservation of cord blood and autologous adult stem cells when the cryopreservation process is completed which is approximately twenty-four hours after cells have been collected. Revenue related to advance payments of storage fees is recognized ratably over the period covered by the advance payments.

The_Business_Tables

The Business (Tables)	9 Months Ended
	Sep. 30, 2013
The Business [Abstract]	'
Subsidiary [Table Text Block]	'
	reporting segment through November 13, 2012, representing the date which the segment was sold (see Note 14). These former segments are reported in discontinued operations.
	Entity	Percentage of Ownership	Location
	NeoStem, Inc.	Parent  Company	United States of America
	NeoStem Therapies, Inc.	100%	United States of America
	Stem Cell Technologies, Inc.	100%	United States of America
	Amorcyte, LLC	100%	United States of America
	Progenitor Cell Therapy, LLC (PCT)	100%	United States of America
	NeoStem Family Storage, LLC	100%	United States of America
	Athelos Corporation (1)	83.30%	United States of America
	PCT Allendale, LLC	100%	United States of America

Loss_Per_Share_Tables

Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2013
Loss Per Share [Abstract]	'
ScheduleOfDilutiveSecuritiesExcludedFromComputationOfEarningsPerShare [Table Text Block]	'
	At September 30, 2013 and 2012, the Company excluded the following potentially dilutive securities:
		September 30,
		2013	2012
	Stock Options	2,840,668	2,238,964
	Warrants	5,054,302	5,631,418
	Series E Preferred Stock, Common stock equivalents	—	236,480
	Restricted Shares	92,000	23,200

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended									9 Months Ended
	Sep. 30, 2013									Sep. 30, 2013
Fair Value Measurements [Abstract]	'									'
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'									'
	For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the three and nine months ended September 30, 2013 by type of instrument (in thousands):
		Three Months Ended				Nine Months Ended
		September 30, 2013				September 30, 2013
		Warrants		Contingent Consideration		Warrants		Contingent Consideration
	Beginning liability balance	$	32.6	$	7,550.00	$	101.2	$	7,550.00
	Change in fair value recorded in earnings	81.5		—		12.9		—
	Ending liability balance	$	114.1	$	7,550.00	$	114.1	$	7,550.00
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis, Valuation Techniques [Table Text Block]	'									'
										The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2013, and December 31, 2012 (in thousands):
											September 30, 2013
											Fair Value Measurements Using Fair Value Hierarchy
											Level 1		Level 2		Level 3
										Warrant derivative liabilities	$	—	$	—	$	114.1
										Contingent consideration	—		—		7,550.00

Goodwill_and_Other_Intangible_1

Goodwill and Other Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2013
Goodwill and Other Intangible Assets [Abstract]	'
Schedule of Finite-Lived Intangible Assets by Major Class [Table Text Block]	'
	The Company's intangible assets and related accumulated amortization as of September 30, 2013 and December 31, 2012 consisted of the following (in thousands):
				30-Sep-13												31-Dec-12
		Useful Life		Gross				Accumulated Amortization				Net				Gross		Accumulated Amortization			Net
	Customer list	10 years		$	1,000.00			$	(270.1	)		$	729.9			$	1,000.00	$	(195.1	)	$	804.9
	Manufacturing technology	10 years		3,900.00				(1,053.4		)		2,846.60				3,900.00		(760.9		)	3,139.10
	Tradename	10 years		800				(216.1		)		583.9				800		(156.1		)	643.9
	In process R&D	Indefinite		9,400.00				—				9,400.00				9,400.00		—			9,400.00
	VSEL patent rights	19 years		669				(202.5		)		466.5				669		(176.1		)	492.9
	Total Intangible Assets			$	15,769.00			$	(1,742.1	)		$	14,026.90			$	15,769.00	$	(1,288.2	)	$	14,480.80
Schedule of Amortization Expense [Table Text Block]	'
	Total intangible amortization expense was classified in the operating expense categories for the periods included below as follows (in thousands):
		Three Months Ended September 30,								Nine Months Ended September 30,
		2013				2012				2013				2012
	Cost of revenue	$	97.5			$	97.5			$	292.5			$	292.5
	Research and development	8.8				8.8				26.4				26.4
	Selling, general and administrative	45				45				135				135
	Total	$	151.3			$	151.3			$	453.9			$	453.9
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	Estimated intangible amortization expense on an annual basis for the succeeding five years is as follow (in thousands):
	2013	$	151.3
	2014	605.2
	2015	605.2
	2016	605.2
	2017	605.2
	Thereafter	11,454.80
		$	14,026.90

Accrued_Liabilities_Accrued_Li

Accrued Liabilities Accrued Liabilities (Tables)	9 Months Ended
	Sep. 30, 2013
Accrued Liabilities [Abstract]	'
Schedule of Accrued Liabilities [Table Text Block]	'
	Accrued liabilities as of September 30, 2013 and December 31, 2012 were as follows (in thousands):
		September 30, 2013		31-Dec-12
	Salaries, employee benefits and related taxes	$	920.8	$	1,597.20
	Professional fees	654.9		606.6
	Other	656.1		81
		$	2,231.80	$	2,284.80

Shareholders_Equity_Tables

Shareholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2013
Shareholdersb Equity [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following table summarizes the activity for stock options and warrants for the nine months ended September 30, 2013:
		Stock Options				Warrants
		Shares			Weighted Average Exercise Price	Shares		Weighted Average Exercise Price
	Outstanding at December 31, 2012	2,168,668			$12.85	5,528,761		$15.65
	Changes during the Year:
	Granted	895,418			7.06	42,835		6.28
	Exercised	(16,369	)		5.29	(401,215	)	5.3
	Forfeited	(86,212	)		5.51	—		—
	Expired	(120,837	)		16.99	(116,079	)	20.61
	Outstanding at September 30, 2013	2,840,668			$11.12	5,054,302		$16.26
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	'
	During the nine months ended September 30, 2013 and 2012, the Company issued warrants for services as follows ($ in thousands, except share data):
			Nine Months Ended September 30,
			2013			2012
	Number of Common Stock Purchase Warrants Issued		20,407			38,500
	Value of Common Stock Purchase Warrants Issued		$	70.5		$	166.2
Restricted Stock [Table Text Block]	'
	During the nine months ended September 30, 2013 and 2012, the Company issued restricted stock for services as follows ($ in thousands, except share data):
			Nine Months Ended September 30,
			2013			2012
	Number of Restricted Stock Issued		452,454			269,727
	Value of Restricted Stock Issued		$	2,967.70		$	1,438.60

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Share-based Compensation [Abstract]	'
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
	The following table summarizes the components of share-based compensation expense for the three and nine months ended September 30, 2013 and 2012 (in thousands):
		Three Months Ended September 30,				Nine Months Ended September 30,
		2013		2012		2013		2012
	Cost of goods sold	$	88.8	$	19.8	$	233.7	$	120.1
	Research and development	319.9		102.2		667		362.4
	Selling, general and administrative	1,718.90		1,794.20		4,511.80		4,988.70
	Total share-based compensation expense	$	2,127.60	$	1,916.20	$	5,412.50	$	5,471.20
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	'
	Total compensation cost related to nonvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at September 30, 2013 were as follows (dollars in thousands):
		Stock Options		Warrants		Restricted Stock
	Unrecognized compensation cost	$	3,101.80	$	16.2	$	588.7
	Expected weighted-average period in years of compensation cost to be recognized	4.07		0.24		0.57
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]	'
	Total fair value of shares vested and the weighted average estimated fair values of shares granted for the nine months ended September 30, 2013 and 2012 were as follows (dollars in thousands):
		Stock Options				Warrants
		Nine Months Ended September 30,				Nine Months Ended September 30,
		2013		2012		2013		2012
	Total fair value of shares vested	$	2,470.00	$	3,637.80	$	123	$	121.6
	Weighted average estimated fair value of shares granted	$	4.3	$	3.63	$	3.45	$	4.32

Discontinued_Operations_Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2013
Balance Sheet [Member] | Regenerative Medicine - China segment [Member]	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	'
	As of March 31, 2012, the Company recognized the following loss on exit of the Regenerative Medicine-China business (in thousands):
	Cash	$	195.1
	Prepaid expenses and other current assets	14.9
	Property, plant and equipment, net	1,023.70
	Other Assets	330.5
	Accounts payable	(177.1		)
	Accrued liabilities	(79.2		)
	Accumulated comprehensive income	(169.9		)
	Loss on exit of segment	$	1,138.00
Balance Sheet [Member] | Pharmaceutical Manufacturing - China business [Member]	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	'
	The Company recognized the following loss on the date of sale of its 51% interest in Erye on November 13, 2012 (in thousands):
	Fair value of consideration received	$	13,397.90
	Carrying value of segment non-controlling interest	6,015.00
	Carrying value of segment accumulated comprehensive income	4,387.40
		$	23,800.30
	Less carrying amount of assets and liabilities sold:
	Cash	$	8,457.50
	Restricted Cash	2,918.10
	Accounts Receivable	6,130.20
	Inventories	15,077.70
	Prepaid expenses and other current assets	957.8
	Property, plant and equipment, net	38,102.00
	Other assets	5,946.30
	Accounts payable	(9,604.8		)
	Accrued liabilities	(2,008.8		)
	Bank loans	(15,133.5		)
	Notes payable	(6,599.3		)
	Other liabilities	(9,166.8		)
	Amount due related party	(7,859.7		)
		$	(27,216.7	)
	Loss on exit of segment	$	(3,416.4	)
Income Statement [Member] | Regenerative Medicine - China segment [Member]	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	'
	The operating results of the Regenerative Medicine – China business for the nine months ended September 30, 2012, which are included in discontinued operations, were as follows (in thousands):
		Nine Months Ended September 30, 2012
	Revenue	$	52.3
	Cost of revenues	(30.6		)
	Research and development	(103.3		)
	Selling, general, and administrative	(497.3		)
	Other income (expense)	(6.8		)
	Loss on exit of segment	(1,138.0		)
	Loss from discontinued operations	$	(1,723.7	)
Income Statement [Member] | Pharmaceutical Manufacturing - China business [Member]	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	'
	The operating results of the Pharmaceutical Manufacturing - China business for the three and nine months ended September 30, 2012, including the estimated asset impairments based on the definitive agreement purchase price as of September 30, 2012, were as follows (in thousands):
		Three Months Ended September 30, 2012			Nine Months Ended September 30, 2012
	Revenue	$	20,036.40		$	57,254.70
	Cost of revenues	(11,551.5		)	(37,131.5		)
	Research and development	(611.8		)	(2,231.5		)
	Selling, general, and administrative	(3,514.7		)	(9,714.8		)
	Other expense	(0.9		)	(1,008.3		)
	Provision for income taxes	(1,029.9		)	(1,535.4		)
	Asset impairments	(3,175.5		)	(31,170.1		)
	Loss on sale of segment	—			—
	Loss from discontinued operations	$	152.1		$	(25,536.9	)

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	'
	A summary of future minimum rental payments required under operating leases that have initial or remaining terms in excess of one year as of September 30, 2013 are as follows (in thousands):
	Years ended	Operating Leases
	2013	$	223.1
	2014	900.9
	2015	726.7
	2016	568.6
	2017	294.7
	Total minimum lease payments	$	2,714.00

The_Business_Details

The Business (Details) (USD $)	0 Months Ended		9 Months Ended	12 Months Ended		9 Months Ended
	Jun. 18, 2012	Jun. 19, 2012	Sep. 30, 2013	Dec. 31, 2011	Dec. 31, 2012	Sep. 30, 2013
	segment	segment			Erye Sale Agreement [Member]	Noncontrolling Interest [Member]
The Company [Line Items]	'	'	'	'	'	'
Change in Ownership in Subsidiary	'	'	$0	'	'	$111,680
Segment Reporting, Additional Information about Entity's Reportable Segments	'	'	'	'three reportable segments	'	'
Number of Reporting Segments	3	1	'	'	'	'
Sale of Stock, Percentage of Ownership before Transaction	'	'	'	'	51.00%	'

The_Business_Principal_of_cons

The Business Principal of consolidation (Details)	9 Months Ended
	Sep. 30, 2013
NeoStem, Inc. [Member] | UNITED STATES	'
Schedule of Subisidiary [Line Items]	'
Minority Interest Ownership Percentage By Parent [String]	'ParentB Company
NeoStem Therapies, Inc [Member] | UNITED STATES	'
Schedule of Subisidiary [Line Items]	'
Subsidiary, Ownership Interest by Parent	100.00%
Stem Cell Technologies, Inc [Member] | UNITED STATES	'
Schedule of Subisidiary [Line Items]	'
Subsidiary, Ownership Interest by Parent	100.00%
Amorcyte, LLC [Member] | UNITED STATES	'
Schedule of Subisidiary [Line Items]	'
Subsidiary, Ownership Interest by Parent	100.00%
China Biopharmaceuticals Holdings, Inc. [Member] | UNITED STATES	'
Schedule of Subisidiary [Line Items]	'
Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest	100.00%
Suzhou Erye Pharmaceuticals Company Ltd. [Member] | CHINA	'
Schedule of Subisidiary [Line Items]	'
Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest	51.00%
Progenitor Cell Therapy, LLC [Member] | UNITED STATES	'
Schedule of Subisidiary [Line Items]	'
Subsidiary, Ownership Interest by Parent	100.00%
NeoStem Family Storage, LLC [Member] | UNITED STATES	'
Schedule of Subisidiary [Line Items]	'
Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest	100.00%
Minority Interest Ownership Percentage By Parent [String]	'1
Athelos Corporation [Member] | UNITED STATES	'
Schedule of Subisidiary [Line Items]	'
Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest	80.10%
Minority Interest Ownership Percentage By Parent [String]	'0.833
PCT Allendale, LLC [Member] | UNITED STATES	'
Schedule of Subisidiary [Line Items]	'
Subsidiary of Limited Liability Company or Limited Partnership, Ownership Interest	100.00%
Minority Interest Ownership Percentage By Parent [String]	'1

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Details) (USD $)	3 Months Ended		6 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Jun. 30, 2012	Sep. 30, 2013
Summary of Significant Accounting Policies [Abstract]	'	'	'	'
Clinical Services Reimbursement	$0.60	$0.90	$2.90	$1.40

Cash_and_Cash_Equivalents_Deta

Cash and Cash Equivalents (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012
Cash and Cash Equivalents [Abstract]	'	'	'
Cash and cash equivalents	$16,946,200	$13,737,452	$5,390,611
Cash, FDIC Insured Amount	$700,000	$800,000	'

Inventories_Details

Inventories (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Schedule of Inventory [Line Items]	'	'
Inventory	$529,366	$1,113,025
Multiple Stage Contracts [Member]	'	'
Schedule of Inventory [Line Items]	'	'
Deferred Revenue	$700,000	$1,200,000

Loss_Per_Share_Details

Loss Per Share (Details)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Warrants	'	'
Class of Stock [Line Items]	'	'
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	5,054,302	5,631,418.20
Series E Preferred Stock, Common stock equivalents	'	'
Class of Stock [Line Items]	'	'
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	0	236,479.90
Stock Options [Member]	'	'
Class of Stock [Line Items]	'	'
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	2,840,668	2,238,964.20
Restricted Stock [Member]	'	'
Class of Stock [Line Items]	'	'
Dilutive Securities Excluded From Computation Of Earnings Per Share, Shares	92,000	23,200

Fair_Value_Measurements_Fair_v

Fair Value Measurements Fair value hierarchy the Companybs financial assets and liabilities (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrant Derivative Liabilities	$0	$0
Contingent Consideration Classified As Equity Fair Value Disclosure	0	0
Fair Value, Inputs, Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrant Derivative Liabilities	0	0
Contingent Consideration Classified As Equity Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrant Derivative Liabilities	114,100	101,200
Contingent Consideration Classified As Equity Fair Value Disclosure	$7,550,000	$7,550,000

Fair_Value_Measurements_Financ

Fair Value Measurements Financial instruments with significant Level 3 inputs (Details) (USD $)	3 Months Ended	9 Months Ended		3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Sep. 30, 2013	Mar. 31, 2013
	Warrants	Warrants	Warrants	contingent cosideration [Member]	contingent cosideration [Member]	contingent cosideration [Member]	contingent cosideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'	'	'	'
Fair Value Inputs, Discount Rate	'	'	'	30.00%	'	'	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'	'	'	'	'	'	'
Beginning liability balance	'	$101,200	$32,600	'	'	$7,550,000	$7,550,000
Change in fair value recorded in earnings	81,500	12,900	'	'	0	0	'
Ending liability balance	$114,100	$114,100	$32,600	$7,550,000	'	$7,550,000	$7,550,000

Goodwill_and_Other_Intangible_2

Goodwill and Other Intangible Assets Intangible Assets and Related Accumulated Amortization (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	$15,769,000	$15,769,000
Finite-Lived Intangible Assets, Accumulated Amortization	-1,742,100	-1,288,200
Finite-Lived Intangible Assets, Net	14,026,900	14,480,800
Customer Lists [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	1,000,000	1,000,000
Finite-Lived Intangible Assets, Accumulated Amortization	-270,100	-195,100
Finite-Lived Intangible Assets, Net	729,900	804,900
Finite-Lived Intangible Assets, Useful Life	'10 years	'
Manufacturing Technology [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	3,900,000	3,900,000
Finite-Lived Intangible Assets, Accumulated Amortization	-1,053,400	-760,900
Finite-Lived Intangible Assets, Net	2,846,600	3,139,100
Finite-Lived Intangible Assets, Useful Life	'10 years	'
Trade Names [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	800,000	800,000
Finite-Lived Intangible Assets, Accumulated Amortization	-216,100	-156,100
Finite-Lived Intangible Assets, Net	583,900	643,900
Finite-Lived Intangible Assets, Useful Life	'10 years	'
In Process R and D [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	9,400,000	9,400,000
Finite-Lived Intangible Assets, Accumulated Amortization	0	0
Finite-Lived Intangible Assets, Net	9,400,000	9,400,000
Finite Lived Intangible Assets, Useful Life [String]	'Indefinite	'
VSEL Patent Rights [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, Gross	669,000	669,000
Finite-Lived Intangible Assets, Accumulated Amortization	-202,500	-176,100
Finite-Lived Intangible Assets, Net	$466,500	$492,900
Finite-Lived Intangible Assets, Useful Life	'19 years	'

Goodwill_and_Other_Intangible_3

Goodwill and Other Intangible Assets Intangible Amortization Expense (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Finite-Lived Intangible Assets [Line Items]	'	'	'	'
Amortization of Intangible Assets	$151,300	$151,300	$453,900	$453,900
Cost of revenue	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'
Amortization of Intangible Assets	97,500	97,500	292,500	292,500
Research and development	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'
Amortization of Intangible Assets	8,800	8,800	26,400	26,400
Selling, general and administrative	'	'	'	'
Finite-Lived Intangible Assets [Line Items]	'	'	'	'
Amortization of Intangible Assets	$45,000	$45,000	$135,000	$135,000

Goodwill_and_Other_Intangible_4

Goodwill and Other Intangible Assets Goodwill (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Goodwill [Abstract]	'	'
Goodwill	$11,117,770	$11,117,770
Future Amortization Expense, Year One	151,300	'
Future Amortization Expense, Year Two	605,200	'
Future Amortization Expense, Year Three	605,200	'
Future Amortization Expense, Year Four	605,200	'
Finite-Lived Intangible Assets, Amortization Expense, Year Five	605,200	'
Thereafter	11,454,800	'
Finite-Lived Intangible Assets, Future Amortization Expense	$14,026,900	$14,480,800

Accrued_Liabilities_Accrued_Li1

Accrued Liabilities Accrued Liabilities (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Accrued Liabilities [Abstract]	'	'
Salaries, employee benefits and related taxes	$920.80	$1,597.20
Professional fees	654.9	606.6
Other	656.1	81
Accrued Liabilities	$2,231.80	$2,284.80

Debt_Details

Debt (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Oct. 31, 2007	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2013	Dec. 06, 2010	Sep. 30, 2013	Dec. 31, 2012
			Convertible Notes Payable [Member]	Convertible Notes Payable [Member]	Convertible Notes Payable [Member]	PCT Allendale, LLC [Member]	PCT Allendale, LLC [Member]	PCT Allendale, LLC [Member]	PCT Allendale, LLC [Member]
							Convertible Notes Payable [Member]	Convertible Notes Payable [Member]	Convertible Notes Payable [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'
Notes Payable	$800,000	$400,000	'	'	'	'	'	'	'
Subordinated Notes to Finance Leveraged Buyout	'	'	3,100,000	'	'	'	1,000,000	'	'
Purchase of condominium units	'	'	3,800,000	'	'	'	'	'	'
Debt Instrument, Frequency of Periodic Payment	'	'	'monthly payments	'	'	'	'	'	'
Debt Instrument, Periodic Payment	'	'	'	'	'	20,766	'	'	'
Debt Instrument, Periodic Payment, Interest	'	'	'	5.00%	'	'	6.00%	'	'
Mortgage Loans on Real Estate, Carrying Amount of Mortgages	'	'	'	2,500,000	2,600,000	'	'	783,700	844,300
Mortgage Loan Repayble Amount within 12 months	'	'	'	'	'	$100,000	'	$100,000	'
Debt Instrument, Period of Loan	'	'	'	'	'	'	'124 months	'	'
Debt Instrument, Period of Fixed Interest Rate	'	'	'	'	'	'	'64 months	'	'

Preferred_Stock_Convertible_Re

Preferred Stock Convertible Redeemable Series E Preferred Stock (Details) (USD $)

9 Months Ended

12 Months Ended

0 Months Ended

0 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Oct. 25, 2012

Nov. 19, 2010

Nov. 19, 2010

Sep. 30, 2013

Nov. 19, 2010

Nov. 19, 2010

Nov. 19, 2010

Sep. 30, 2013

Dec. 31, 2012

Series E Seven Percent Senior Convertible Preferred Stock [Member]

Warrant to purchase 0.25 of a share of Common Stock [Member]

Warrant to purchase 0.25 of a share of Common Stock [Member]

Warrant to purchase 0.0155 of a share of Common Stock [Member]

Preferred Offering Unit [Member]

Fair Value, Inputs, Level 3 [Member]

Fair Value, Inputs, Level 3 [Member]

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Offering Units

'

'

'

'

10,582,011

'

'

'

'

'

'

'

Preferred Stock, Dividend Rate, Percentage

'

'

'

'

'

7.00%

'

'

'

'

'

'

Preferred stock, par value

$0.01

'

$0.01

'

$0.01

'

'

'

'

'

'

'

Stock and Warrants Issued During Period, Shares, Preferred Stock and Warrants

'

'

'

'

'

'

199,031

132,249

16,442

'

'

'

Sale of Stock, Price Per Share

'

'

'

'

$0.95

'

'

'

'

'

'

'

Net proceeds from issuance of capital stock

$21,517,422

$12,160,227

'

'

'

'

'

'

'

$10,000,000

'

'

Net Proceeds from Issuance or Sale of Equity

'

'

'

'

'

'

'

'

'

8,900,000

'

'

Preferred Stock, Shares Outstanding

10,000

'

10,000

2,351,558

'

'

'

'

'

'

'

'

Common stock issued in payment of dividends for the Convertible Redeemable Series E 7% Preferred Stock

'

'

3,400,000

'

'

'

'

'

'

'

'

'

Proceeds from (Repurchase of) Redeemable Preferred Stock

'

'

2,500,000

'

'

'

'

'

'

'

'

'

Payments of Dividends, Preferred Stock and Preference Stock

'

'

3,100,000

'

'

'

'

'

'

'

'

'

Payments for Repurchase of Redeemable Preferred Stock

'

'

200,000

'

'

'

'

'

'

'

'

'

Increase (Decrease) in Interest Payable, Net

'

'

36,000

'

'

'

'

'

'

'

'

'

Warrant Derivative Liabilities

'

'

'

'

'

'

'

'

'

'

$114,100

$101,200

Shareholders_Equity_Equity_Iss

Shareholders' Equity Equity Issuances (Details) (USD $)	9 Months Ended				0 Months Ended			0 Months Ended		2 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Nov. 19, 2010	Sep. 30, 2012	Sep. 30, 2011	Sep. 28, 2011	3-May-13	1-May-13	Feb. 28, 2013	Sep. 30, 2013
					Private Placement [Member]	Aspire Capital Purchase Agreement [Member]	Aspire Capital Purchase Agreement [Member]	Aegis Capital Purchase Agreement [Member]	Aegis Capital Purchase Agreement [Member]	Aspire Capital Purchase Agreement [Member]	Aspire Capital Purchase Agreement [Member]
Class of Stock [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Committment Value Under Purchase Agreement	'	'	'	'	'	'	$20,000,000	'	'	'	'
Term Of Agreement In Months	'	'	'	'	'	'	24	'	'	'	'
Discount Applied To Weighted Average Price	'	'	'	'	'	'	5.00%	'	'	'	'
Shares, Issued	'	'	'	'	'	99,010	'	'	'	'	'
Warrant Inducements (in shares)	'	'	'	'	161,290	'	'	'	'	'	'
Investment Warrants, Exercise Price	'	'	'	'	$6	'	'	'	'	'	'
Shares, Issued	'	'	'	'	'	'	'	'	2,000,000	'	'
Sale of Stock, Price Per Share	'	'	'	$0.95	'	'	'	'	$5	'	'
Proceeds from Issuance of Common Stock Gross	'	'	'	'	'	'	'	11,500,000	'	'	'
Common Stock, Shares, Issued	21,193,870	'	16,375,365	'	'	'	'	'	300,000	1,639,659	'
Net proceeds from issuance of common stock	21,517,422	12,160,227	'	'	'	'	'	'	'	11,100,000	'
Purchase Commitment, Remaining Minimum Amount Committed	'	'	'	'	'	'	'	'	'	'	$5,600,000

Shareholders_Equity_Warrant_Ex

Shareholders' Equity Warrant Exercises (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Stock Options and Warrants [Line Items]	'	'
Proceeds from exercise of warrants	$2,126,291	$5,925,931
Underwriting Offering [Member]	'	'
Stock Options and Warrants [Line Items]	'	'
Class of Warrant or Right, fair value of warrant inducement	$0	'

Shareholders_Equity_Stock_opti

Shareholders' Equity Stock options and warrants (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012
Stock Options and Warrants [Line Items]	'	'	'
Stock Issued During Period, Shares, Other	20,407	38,500	'
Warrants Issued During Period, Value	$70,500	$166,200	'
Common Stock Warrants, Shares	5,054,302	'	5,528,761
Weighted Average Exercise Price, Warrants Outstanding	16.26	'	15.65
Warrants Granted	42,835	'	'
Weighted Average Exercise Price, Warrants Granted	$6.28	'	'
Warrants Exercised	401,215	'	'
Weighted Average Exercise Price, Warrants Exercised	$5.30	'	'
Warrants Expired	0	'	'
Weighted Average Exercise Price, Warrants Expired	$0	'	'
Warrants Canceled	116,079	'	'
Weighted Average Exercise Price, Warrants Canceled	$20.61	'	'
US Equity Plan [Member]	'	'	'
Stock Options and Warrants [Line Items]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	2,840,668	'	2,168,668
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$11.12	'	$12.85
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	895,418	'	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$7.06	'	'
Stock Options Exercised	-16,369	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	$5.29	'	'
Stock Options Expired	-86,212	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price	$5.51	'	'
Stock Options Forfeited	-120,837	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price	$16.99	'	'

Shareholders_Equity_Restricted

Shareholders' Equity Restricted Stock (Details) (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock Issued During Period, Shares, Restricted Stock Award, Gross	452,454	269,727
Stock Issued During Period, Value, Restricted Stock Award, Gross	$2,967,700	$1,438,600
weighted average estimated fair value of restricted stock	$6.56	$5.33

ShareBased_Compensation_ShareB

Share-Based Compensation Share-Based Compensation (Details) (USD $)

3 Months Ended

9 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2013

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Sep. 30, 2013

Sep. 30, 2012

Stock Option [Member]

Warrants

Warrants

Warrants

Stock Options [Member]

Stock Options [Member]

Restricted Stock [Member]

Cost of revenue

Cost of revenue

Cost of revenue

Cost of revenue

Research and development

Research and development

Research and development

Research and development

Selling, general and administrative

Selling, general and administrative

Selling, general and administrative

Selling, general and administrative

Stock Option [Member]

Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Allocated Share-based Compensation Expense

$2,127,600

$1,916,200

$5,412,500

$5,471,200

'

'

'

'

'

'

'

$88,800

$19,800

$233,700

$120,100

$319,900

$102,200

$667,000

$362,400

$1,718,900

$1,794,200

$4,511,800

$4,988,700

'

'

Unrecognized compensation cost

'

'

'

'

3,101,800

16,200

'

'

'

'

588,700

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected weighted-average period in years of compensation cost to be recognized

'

'

'

'

'4 years 26 days

'2 months 27 days

'

'

'

'

'6 months 26 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total fair value of shares vested

'

'

'

'

'

$123,000

$121,600

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2,470,000

$3,637,800

Weighted average estimated fair value of shares granted

'

'

'

'

'

$3.45

'

$4.32

$4.30

$3.63

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income_Taxes_Net_Operating_Los

Income Taxes Net Operating Loss Carry Forward (Details) (USD $)	12 Months Ended
	Dec. 31, 2012	Sep. 30, 2013
Operating Loss Carryforwards [Line Items]	'	'
Operating Loss Carryforwards, Limitations on Use	'25994800	'
Operating Loss Carryforwards, Valuation Allowance	$8,800,000	'
Operating Loss Carryforwards	69,700,000	'
Deferred Tax Liabilities, Net, Noncurrent	$3,599,122	$4,091,447

Discontinued_Operations_Compan

Discontinued Operations Company recognized loss on exit (Details) (Regenerative Medicine - China segment [Member], USD $)	1 Months Ended		6 Months Ended	1 Months Ended
	Mar. 31, 2012	Mar. 31, 2012	Jun. 30, 2012	Mar. 31, 2012	Mar. 31, 2012	Mar. 31, 2012	Mar. 31, 2012	Mar. 31, 2012
		Gain (Loss) on Dispostion of Cash and Cash Equivalents [Member]	Gain (Loss) on Disposition of Prepaid Expenses and Other Current Assets [Member]	Gain (Loss) on Disposition of Property, Plant and Equipment, Net [Member]	Gain (Loss) on Disposition of Other Assets [Member]	Gain (Loss) on Disposition of Accounts Payable [Member]	Gain (Loss) on Disposition of Accrued Liabilities [Member]	Gain (Loss) on Disposition of Accumulated Comprehensive Income [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'	'	'	'	'
Loss on exit of segment	$1,138,000	$195,100	$14,900	$1,023,700	$330,500	($177,100)	($79,200)	($169,900)

Discontinued_Operations_The_op

Discontinued Operations The operating results of the Regenerative Medicine b China business (Details) (Regenerative Medicine - China segment [Member], USD $)	9 Months Ended
	Sep. 30, 2012
Regenerative Medicine - China segment [Member]	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'
Disposal Group, Including Discontinued Operation, Revenue	$52,300
Disposal Group, Including Discontinued Operation, Costs of Goods Sold	-30,600
Disposal Group Including Discontinued Operation Research and Development	-103,300
Disposal Group Including Discontinued Operation Selling General and Administrative	-497,300
Disposal Group, Including Discontinued Operation, Operating Expense	-6,800
Loss on Exit of Segment	-1,138,000
Disposal Group, Including Discontinued Operation, Operating Income (Loss)	($1,723,700)

Discontinued_Operations_The_su

Discontinued Operations The summary of assets and liabilities related to Regenerative Medicine - China business (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012
Assets:	'	'	'
Cash and cash equivalents	$0	'	$10,789,480
Assets of Disposal Group, Including Discontinued Operation	'	$23,800,300	'

Discontinued_Operations_The_op1

Discontinued Operations The operating results of pharmaceutical manufacturing - China business (Details) (Pharmaceutical Manufacturing - China business [Member], USD $)	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2012	Sep. 30, 2012	Dec. 31, 2012
Pharmaceutical Manufacturing - China business [Member]	'	'	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'
Disposal Group, Including Discontinued Operation, Revenue	$20,036,400	$57,254,700	'
Disposal Group, Including Discontinued Operation, Costs of Goods Sold	-11,551,500	-37,131,500	'
Disposal Group Including Discontinued Operation Research and Development	-611,800	-2,231,500	'
Disposal Group Including Discontinued Operation Selling General and Administrative	-3,514,700	-9,714,800	'
Disposal Group, Including Discontinued Operation, Operating Expense	-900	-1,008,300	'
Discontinued Operation, Provision for Loss (Gain) on Disposal, before Income Tax	-1,029,900	-1,535,400	'
Disposal Group Including Discontinued Operation Assets Impairment	-3,175,500	-31,170,100	'
Loss on exit of segment	0	0	3,416,400
Disposal Group, Including Discontinued Operation, Operating Income (Loss)	$152,100	($25,536,900)	'

Discontinued_Operations_The_su1

Discontinued Operations The summary of the assets and liabilities related to Pharmaceutical Manufacturing- China discontinued operations (Details) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Sep. 30, 2012	Sep. 30, 2012	Dec. 31, 2012	Nov. 13, 2012	Dec. 31, 2012
				Pharmaceutical Manufacturing - China business [Member]	Pharmaceutical Manufacturing - China business [Member]	Pharmaceutical Manufacturing - China business [Member]	Pharmaceutical Manufacturing - China business [Member]	Equity Purchase Agreement [Member]
								CBH Acquisition LLC [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'	'	'	'	'
Disposal Group, Including Discontinued Operation, Accrued Liabilities	'	'	'	'	'	($2,008,800)	'	'
Equity Method Investment, Ownership Percentage	'	'	'	'	'	'	'	51.00%
Available-for-sale Securities, Fair Value Disclosure	'	'	'	'	'	13,397,900	'	'
Noncontrolling interests	-565,170	-356,970	'	'	'	6,015,000	'	'
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	'	'	'	'	'	4,387,400	'	'
Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents	0	'	10,789,480	'	'	8,457,500	'	'
Cash and cash equivalents	16,946,200	13,737,452	5,390,611	'	'	'	12,300,000	'
Restricted cash	'	'	'	'	'	2,918,100	'	'
Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net	'	'	'	'	'	6,130,200	'	'
Inventory	'	'	'	'	'	15,077,700	'	'
Prepaid expenses and other current assets	'	'	'	'	'	957,800	'	'
Property, plant and equipment, net	'	'	'	'	'	38,102,000	'	'
Other assets	'	'	'	'	'	5,946,300	'	'
Disposal Group, Including Discontinued Operation, Accounts Payable	'	'	'	'	'	9,604,800	'	'
Total assets	'	23,800,300	'	'	'	'	'	'
Bank loans	'	'	'	'	'	-15,133,500	'	'
Notes payable	'	'	'	'	'	-6,599,300	'	'
Unearned revenue	'	'	'	'	'	-9,166,800	'	'
Amount due related parties	'	'	'	'	'	-7,859,700	'	'
Total Liabilities	'	'	'	'	'	-27,216,700	'	'
Loss on exit of segment	'	'	'	$0	$0	($3,416,400)	'	'
Treasury Stock, Shares	'	'	'	'	'	'	104,000	'
Stock Option Cancelled	'	'	'	'	'	'	117,000	'
Warrants Cancelled	'	'	'	'	'	'	64,000	'

Related_Party_Transactions_Det

Related Party Transactions (Details) (Equity Purchase Agreement [Member])	Dec. 31, 2012	Jun. 18, 2012
	CBH Acquisition LLC [Member]	EET and Fullbright [Member]
Related Party Transaction [Line Items]	'	'
Equity Method Investment, Ownership Percentage	51.00%	'
Noncontrolling Interest, Ownership Percentage by Parent	'	49.00%

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	3 Months Ended		6 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Jun. 30, 2012	Sep. 30, 2013
Operating Leases, Future Minimum Payments Due [Abstract]	'	'	'	'
2013	$223,100	'	'	$223,100
2014	900,900	'	'	900,900
2015	726,700	'	'	726,700
2016	568,600	'	'	568,600
Thereafter	294,700	'	'	294,700
Total minimum lease payments	2,714,000	'	'	2,714,000
Operating Leases, Rent Expense	$300,000	$400,000	$1,200,000	$900,000

Subsequent_Events_Details

Subsequent Events (Details) (USD $)

9 Months Ended

0 Months Ended

1 Months Ended

1 Months Ended

Sep. 30, 2013

Sep. 30, 2012

Dec. 31, 2012

Nov. 19, 2010

3-May-13

1-May-13

Jul. 26, 2013

Sep. 30, 2013

Nov. 05, 2013

Nov. 05, 2013

Jul. 26, 2013

Jul. 26, 2013

Aegis Capital Purchase Agreement [Member]

Aegis Capital Purchase Agreement [Member]

Aegis Capital Purchase Agreement [Member]

Aegis Capital Purchase Agreement [Member]

Stock Option [Member]

Underwriting Offering [Member]

Underwriting Offering [Member]

Stock Options [Member]

Issuance of Equity [Member]

Issuance of Equity [Member]

Stock Options [Member]

Warrants

Warrants

Subsequent Event [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Shares, Issued

'

'

'

'

'

2,000,000

'

5,000,000

'

'

'

'

Common Stock, Par Value

$0.00

'

$0.00

'

'

'

'

'

'

'

'

'

Sale of Stock, Price Per Share

'

'

'

$0.95

'

$5

'

$7

'

'

'

'

Common Stock, Shares, Issued

21,193,870

'

16,375,365

'

'

300,000

'

750,000

'

'

'

'

Proceeds from Issuance of Common Stock Gross

'

'

'

'

$11,500,000

'

$40,300,000

'

'

'

'

'

Class of Warrant or Right, Additional Number of Securities Called by Warrants or Rights

'

'

'

'

'

'

'

'

'

'

161,951

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

'

'

'

'

'

'

'

'

'

'

5.1

'

Exercise price of Warrants

'

'

'

'

'

'

'

'

'

'

7

'

Proceeds from exercise of warrants

2,126,291

5,925,931

'

'

'

'

'

'

'

900,000

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number

'

'

'

'

'

'

'

'

'

'

'

15,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price

'

'

'

'

'

'

'

'

'

'

'

$4

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price

'

'

'

'

'

'

'

'

'

'

'

$4.40

Proceeds from Stock Options Exercised

$86,658

$0

'

'

'

'

'

'

$100,000

'

'

'